Pricing Log in Create free account

Acumen Pharmaceuticals, Inc. (ABOS) vs AN2 Therapeutics, Inc. (ANTX)

Acumen Pharmaceuticals, Inc. and AN2 Therapeutics, Inc. are both Biotechnology companies. AN2 Therapeutics, Inc. is the larger, with a market value of $135.9M against $120.8M — 1.1× the size. Across the 9 metrics below, AN2 Therapeutics, Inc. leads on 7 and Acumen Pharmaceuticals, Inc. on 2.

Valuation

Metric ABOS ANTX Biotechnology median
P/E n/m n/m 8.42
P/S 84.02 n/m 10.01
P/B 2.11 2.12 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales 29.27 n/m 9.41
Earnings yield (97.60%) (29.81%) (31.85%)
Free cash flow yield (76.15%) (19.09%) (24.58%)

Profitability

Metric ABOS ANTX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (120.50%) (50.12%) (56.36%)
Return on assets (72.97%) (46.06%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ABOS ANTX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (16.96%) 32.56% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS ANTX Biotechnology median
Debt to equity 0.55 0.00 0.00
Current ratio 2.47 14.32 4.72
Net debt to EBITDA 0.69 1.48 0.96

Dividend

Metric ABOS ANTX Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ABOS ANTX Biotechnology median
Market cap 120.77m 135.85m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack